The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study
Clinical drug investigation March 1, 2022 Anton L. V. Avanceña, J. Kahn, E. Marseille 19 citations
Expanding access to MDMA-assisted psychotherapy (MDMA-AT) for US patients with chronic and severe PTSD would likely provide substantial health and financial benefits. A decision-analytic model compared three coverage targets (25%, 50%, and 75% of eligible patients) against standard care. All three targets were cost-saving and projected to avert 43,618 to 106,932 deaths and gain 3.3 to 8.2 million quality-adjusted life years over 10 years. Sensitivity analyses confirmed that MDMA-AT remained dominant under various assumptions, though the precise magnitude of benefits depends on the number of eligible patients and other inputs.